OIPE JC185 APR 08 2004 PATENT & TRADEMARK OFFICE

PATENT

Case Docket No. MAXIM.078CP1
Date: April 6, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Hellstrand et al.
Appl. No.	:	10/680,865
Filed	:	October 07, 2003
For	:	REACTIVE OXYGEN METABOLITE INHIBITORS FOR USE IN COMPOSITIONS AND METHOD OF TREATEMENT
Examiner	:	Unknown
Group Art Unit	:	1646

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 6, 2004
(Date)

Marc C. Baumgartner, Reg. No. 53,976

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

(X) An Information Disclosure Statement.

(X) A PTO Form 1449 with sixty-five (65) references listed.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

(X) Return prepaid postcard.

Marc C. Baumgartner
Registration No. 53,976
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\MCB\MCB-2615.DOC
040604

OIPE
APR 0 8 2004
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Applicant	:	Hellstrand et al.
App. No.	:	10/680,865
Filed	:	October 07, 2003
For	:	REACTIVE OXYGEN METABOLITE INHIBITORS FOR USE IN COMPOSITIONS AND METHODS OF TREATEMENT
Examiner	:	Unknown
Group Art Unit	:	1646

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing sixty-five (65) references that are of record in U.S. patent application No. 09/616,622, filed July 14, 2000, which is the parent of this Continuation-in-Part application, and is relied upon for an earlier filing date under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C:F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 4/6/04

By: Marc Baumgartner
Marc C. Baumgartner
Registration No. 53,976
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\MCB\MCB-2614.DOC
040604

OIPE JC185 APR 08 2004 PATENT & TRADEMARK OFFICE

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MAXIM.078CP1	APPLICATION NO. 10/680,865
	APPLICANT Hellstrand, et al.	
	FILING DATE October 07, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,348,739	09/20/94	Hellstrand et al.			
	2	3.862,333	01/21/75	Chalupa et al.			
	3	5,780,513	07/14/98	McDaniel et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	4	WO 96/10402	04/11/96	PCT				
	5	WO 00/40229	07/13/00	PCT				

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	6	Alderson et al. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J.Exp.Med. 181:71-77.
	7	Allen et al. (1997) Morphological and biochemical characterization and analysis of apoptosis. JPM. 37:4:215-228
	8	Armstrong et al. (1998) Tumor antigen presentation: changing the rules. Cancer Immunol Immunother. 46:70-74
	9	Asea et al (1996) Histaminergic Regulation of Natural Killer Cell-Mediated Clearance of Tumour Cells in Mice. Scand. J. Immunol. 43:9-15
	10	Barna et al. (1983) Tumor-Enchancing effects of cimetidine. Oncology. 40:43-45.
	11	Bauer et al. (1998) Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. J.Bio.Chem. 273:14:8048-8055.
	12	Barhoumi et al. (1993) concurrent analysis of intracellular glutathione content and gap junctional intercellular communication. Cytometry. 14:747-756.
	13	Becker et al. (1996) T Cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J.Exp.Med. 183:2361-66.
	14	Buggins et al. (1998) Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. British J. of Haematology. 100:784-792.
	15	Bottazzi et al. (1992) Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility of IL-2 therapy of a murine melanoma[1]. J.of Immuno. 148:1280-1285.
	16	Brunda et al. (1987) In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling nature killer cells. Int.J.Cancer. 40:365-371.
	17	Brune et al. (1996) Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. British J. of Haematology. 92:620-626.
	18	Birtin et al. (1981) The influence of intraperitoneal injections of histamine on tumour growth in fibrosarcoma-bearing mice. Cancer letters. 12:195-201.
	19	Buttke et al. (1994) Oxidative stress as a mediator of apoptosis. Immunology Today. 15:1:7-10.
	20	Cao et al. (1998) Interleukin 15 protecgs against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Reserach. 58:1695-1699.

S:\DOCS\JJM\JJM-5079.DOC\112700
S:\DOCS\MCB\MCB-2449.DOC
012204

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.078CP1	APPLICATION NO. 10/680,865
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE October 07, 2003	GROUP 1646

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	21	Dohlsten et al. (1986) Synergistic action of gamma interferon and catalase to reverse the suppressive effect of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation. Scand.J.Immunol. 24:49-58.
	22	Dröge et al. (1994) Functions of glutathione and glutathione disulfide in immunology and immunopathology. The FASEB Journal. 8:1131-1138.
	23	Dumont et al. (1999) Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-κB. Oncogene. 18:747-757.
	24	Dutcher et al. (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J.of clin.Onco. 7:4:477-485.
	25	Fao et al. (1991) Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. British J. of Haematology. 77:491-496.
	26	Hansson et al. (1996) Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. of Immuno. 42-47.
	27	Hawkins, M.J. (1993) Interleukin-2 antitumor and effector cell responses. Seminars in Oncology. 20:6:52-59.
	28	Hellstrand et al. (1986) Histamine h2-receptor-mediated regulation of human natural killer cell activity. J.of Immuno. 137:2:656-660.
	29	Hellstrand et al. (1990) Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int.Arch.Allergy App. Immuno. 92:379-389.
	30	Hellstrand et al. (1990) Role ofhistamine in natural killer cell-mediated resistance against tumor cells. J.of Immuno. 145:4365-4370.
	31	Hellstrand et al. (1991) Monocyte-induced down-modulation of CD16 and CD56 antigesn on human natural killer cells and its regulation by histaime H2-receptors. Cellular Immuno. 138:44-54.
	32	Hellstrand et al. (1994) Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. J. of Leukocyte Biology. 55:392-397.
	33	Hellstrand et al. (1994) Histaminergic regulation of NK cells. J. of Immuno. 153:4940-4947.
	34	Hellstrand et al. (1994) Histamine in immunotherapoy of advanced melanoma: a pilot study. Cancer Immuno.Immunother. 39:416-419.
	35	Hellstrand et al. (1995) Role of histamine in natural killer cell-dependent protection against herpers simplex virus type 2 infection in mice. Clin.Diagn.Lab.Immunol. 2:3:277-280.
	36	Hellstrand et al. (1997) Histamine and interleukin-2 in acute myelogenous leukemia. Leukemia and Lymphoma. 27:429-438.
	37	Johansson et al. (1998) The response of dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. British J. of Cancer. 77:8:1213-1219.
	38	Klebanoff, S.J.ygen-dependent cytotoxic meechanisms of phagocytes. Advances in Host Defense Mechanisms. 1:111-162.
	39	Kono et al. (1996) Hydrogen peroxide secreted by tumor-derived machrophages down-modultes signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur.J.Immunol. 26:1308-1313.
	40	Lanier et al. (1988) Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the leu-23 activation antigen. J.Exp.Med. 167:1572-1585.
	41	Linden et al. (1987) Catalase and lipopolysaccharide enhance proliferation in the rat mixed lymphocyte reaction. Scand.J.Immunol. 26:223-228.
	42	Lundqvist et al. (1996) Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. Free Radical Biology & Medicine. 20:6:785-792.
	43	Mantovani et al. (1992) The origin and function of tumor-associated macrophages. Immunology Today. 13:7:265-270.
	44	Matsuda et al. (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int.J.Cancer. 61: 765-772.
	45	Medvediv et al. (1997) Regulation of fas and fas-ligand expression in NK cells by cytokines and the involvement of fas-ligand in NK/LAK cell-medited cytotoxicity. Cytokine. 9:6:394-404.
	46	Miesel et al. (1996) Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and nadph oxidase. Free Radical Biology & Medicine. 20:1:75-81.

S:\DOCS\JJM\JJM-5079.DOC\112700
S:\DOCS\MCB\MCB-2449.DOC
012204

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.078CP1	APPLICATION NO. 10/680,865
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE October 07, 2003	GROUP 1646

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	47	Mizoguchi et al. (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1795-1798.
	48	Motzer et al. (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advnaced renal cell carcinoma. Clinical Cancer Research. 4:1183-1191.
	49	Nordlund et al. (1983) The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. J. of Investigative Dermatology. 81:1:28-31.
	50	Osband et al. (1981) Successful tumour immunotherapy with cimetidine in mice. The Lancet. 636-638.
	51	Otsuji et al. (1996) Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ξ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc.Ntl.Acad.Sco. 93:13119-13124.
	52	Plaut et al. (1982) Histamine and immune responses. Pharmacology of Histamine Receptors. 392-435.
	53	Rabinowich et al. (1996) Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clinical Cancer Research. 2:1263-1274.
	54	Rosenberg et al. (1987) A progress report on the treatment of 157 ptients with andanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine. 316:15:889-897.
	55	Rosenberg, S.A. (1988) The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann.Surg. 208:2:121-135.
	56	Slater et al. (1995) Signalling mechanisms and oxidative stress in apoptosis. Toxicology Letters. 149-153.
	57	Smith, K.A. (1988) Interleukin-2: inception, impact,a nd implications. Science. 240:1169-1176.
	58	Smith, K.A. (1988) Interleukin 2. Academic Press, Inc. ISBN 0-12-651420-8. 9 pps.
	59	Trinchieri, G. (1989) Biology of natural killer cells. Advances in Immunology. 47:187-376.
	60	Triozzi et al. (1995) Phase I trial of escalating doses of interleukin-1β in combination with a fixed dose of interleukin-2. Journal of clinical oncology. 13:2:482-489.
	61	Whiteside et al. (1993) Natural killer cells and tumor therapy. Curr.Top.Microbiol.Immunol. 230:221-244.
	62	Whiteside, T.L. (1998) Immune cells in the tumor microenvironment. Adv.Exp.Mod.Biol. 451:167-171.
	63	Yasaka et al. (1981) Functions of human monocyte and lymphocyte subsets obtained by countercurrent centrifugal elutriation: differing functional capacities of human monocyte subsets. J. of Immunol. 127:1515-1518.
	64	Yim et al. (1994) Use of N-acetyl cysteine to increse intracellular glutathione during the induction of antitumor responses by IL-2[1]. J.Immunol. 152:5796-5805.
	65	Zea et al. (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients[1]. Clin.Cancer Res. 1:1327-1335.

S:\DOCS\JJM\JJM-5079.DOC\112700
S:\DOCS\MCB\MCB-2449.DOC
012204

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.